No evidence electric charge increases inhaled ultrafine particle deposition in human lungs Source: Virtual Congress 2020 – Occupational and environmental causes of respiratory disease Year: 2020
A novel breath-actuated vortex spacer device increases respirable dose delivery of fluticasone/salmeterol in combination Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008
Gamma-scintigraphic evaluation of the delivered dose, lung deposition rate and distribution pattern of 99m Tc-labelled tiotropium via dry powder inhaler Source: Eur Respir J 2003; 22: Suppl. 45, 475s Year: 2003
Slow particle dissolution may limit lung absorption of inhaled pharmaceuticals in the lungs Source: Eur Respir J 2006; 28: Suppl. 50, 210s Year: 2006
Reduction of treatment time for nebulized treatments using a new adaptive aerosol delivery mode Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008
Effect of device and formulation on delivery of budesonide suspensions by nebulizers Source: Eur Respir J 2002; 20: Suppl. 38, 542s Year: 2002
Dose proportionality of in vitro fine particle dose for dry powder inhaler combination products Source: Eur Respir J 2002; 20: Suppl. 38, 541s Year: 2002
Measuring peripheral lung dimensions with the deposition of aerosol nanoparticles Source: Virtual Congress 2021 – Management of chronic cough and obstructive diseases Year: 2021
Effect of nebuliser position on aerosol performance during high flow nasal therapy Source: International Congress 2018 – New tools for managing respiratory failure Year: 2018
Effect of inhaled corticosteroids depends on its particle size Source: Annual Congress 2009 - Models of chronic airways disease and therapy Year: 2009
Ex-vivo emitted dose characteristics for combination formulations in dry powder inhalers (DPI) Source: Eur Respir J 2003; 22: Suppl. 45, 472s Year: 2003
Numerical simulation of the effect of inhalation parameters and disease severity on the deposition of dry powder aerosol drugs in COPD patients Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more Year: 2020
Performance characteristics of a multi dose dry powder inhaler (MDPI) with respect to the use of different deaggregation systems Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004
Influence of nebulizer type, position and bias flow on aerosol drug delivery to a pediatric model of mechanical ventilation Source: Annual Congress 2008 - Respiratory disorders in paediatric intensive care unit Year: 2008
Aerosol particle size output from a new nebuliser system, measured by cascade impaction Source: Eur Respir J 2005; 26: Suppl. 49, 125s Year: 2005
Assessment of lung deposition and pharmacokinetics in 12 lung transplanted patients after inhalation of a novel liposomal ciclosporin a (CsA) formulation by the eFlow electronic nebuliser Source: Eur Respir J 2007; 30: Suppl. 51, 29s Year: 2007
Comparison of amosite and wollastonite fibre effects on selected BAL parameters and lung tissue injury-time and dose dependence Source: Eur Respir J 2002; 20: Suppl. 38, 126s Year: 2002
Systemic availability (lung deposition) of drug from two different dry powder inhalers in children with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 429s Year: 2002
Single-breath, real time measurement of lung deposition of tobacco smoke fine particles: the correlation between particle burden and regional particle deposition fraction Source: Annual Congress 2007 - The versatile aspects of nicotine addiction Year: 2007
Determination of tissue concentrations of metabolites in surgical preparations following inhalation of beclomethasone-dipropionate using conventional and extrafine aerosols Source: Eur Respir J 2003; 22: Suppl. 45, 472s Year: 2003